The Agonist Immunotherapy Targets conference at PEGS Europe will showcase the expanding formats and design principles toward agonist targets and pathways; discuss strategies to enhance specificity and reduce toxicity; and present the latest updates and lessons learned from molecules in preclinical to clinical development.
KEYNOTE PRESENTATION: Agonists to the TNF Superfamily: Lessons Learned for TNFR1 for Autoimmunity
Denise L. Faustman, MD, PhD, Director, Immunology, Massachusetts General Hospital; Associate Professor, Medicine, Harvard Medical School
CD137/4-1BB and OX40
CTX-471, a CD137 Agonist Undergoing Clinical Development in Patients with Advanced Solid Tumors
Thomas J. Schuetz, MD, PhD, Founder and CEO, Compass Therapeutics
T-Cell Enhancers for Focused CD137/4-1BB Co-Stimulation in the Tumor Microenvironment
James Legg, PhD, Senior Vice President Research, Crescendo Biologics
Multispecific and Multivalent Antibodies as OX40 Agonists
Mandar Badaweder, PhD, Vice President Research, Invenra
Bispecific Agonistic Antibodies for Tumor Directed Immunotherapy
Peter Ellmark, PhD, Vice President Discovery, Alligator Bioscience AB
CD40, GITR, and ICOS
Tumor Localized Agonistic Anti-CD40 Therapy and Beyond
Sara Mangsbo, PhD, Associate Professor, Uppsala University
Emergence of ICOS hi CD4 T Cells Correlates with Tumor Reduction, Progression-Free Survival, and Overall Survival in Advanced Cancer Patients Treated with Vopratelimab, an ICOS Agonist
Elizabeth Trehu, PhD, CMO, Jounce Therapeutics, Inc.
HERA-GITRL: A Unique Hexavalent GITRL Agonist for Cancer Immunotherapy
Oliver Hill, PhD, Vice President, Drug Discovery/Lead Optimization, Apogenix AG
ONCOLYTIC VIRUS AND COMBINATION THERAPIES
Development of ONCR-177, a Mir-Attenuated Oncolytic HSV-1 Designed to Potently Activate Systemic Anti-Tumor Immunity
Christophe Queva, PhD, CSO, Oncorus, Inc.
* The program is subject to change without notice, due to unforeseen reason.